Market Date:28 March, 2020

Medical cannabis in New Zealand with Medical Kiwi

Medical Kiwi are in the forefront of initiating medical cannabis in New Zealand, here we know about their strategies within this exciting sector.

New Zealand is now under a ‘green rush’ after the government’s decision to pass laws last year paving the way for national, commercial farming and manufacture of medicinal cannabis. But with this recently established laws permitting the use of medical cannabis in New Zealand, several New Zealand based businesses are now rushing to maintain line to capitalise on the legislative shift and Medical Kiwi is nicely positioned for initial benefit.

Far from being a spur-of-the-moment choice, Medical Kiwi co-founder Aldo Miccio’s venture to medical cannabis was considered as well as non-meat. “The benefit of New Zealand being one of the most recent countries to change legislation is that we’ve been able to watch what has been happening in the global industry, read the research and listen to the success stories,” Miccio states.

“Medicinal and nutraceutical cannabis products had been on my radar for years, but it was the opportunity to meet with a large Canadian company that really helped me to understand the business model and potential of the market. We were just waiting for an opportunity to present itself in New Zealand.”

That chance arrived in December 2018 with laws in New Zealand moving down a road to fully commercialise a medicinal and nutraceutical cannabis market. The details which will govern the sector continue to be finalised with New Zealand’s Ministry of Health leading work to develop a medicinal cannabis scheme. The Ministry of Health’s public consultation about the proposals for its medicinal cannabis regulations happened in July 2019 with regulations to be produced in December and also the medicinal cannabis strategy operational at the first quarter of 2020.

Based on Miccio, the understanding about medicinal cannabis in New Zealand remains in its infancy however is shifting as more evidence comes out because of its effectiveness. “With people’s experiences being supported by medical research which continues to identify the therapeutic effects of medicinal cannabis for a range of ailments and conditions, society’s views about medicinal cannabis is evolving,” he states. A survey commissioned by the New Zealand Drug Foundation at 2018 discovered that 87percent of New Zealanders currently encourage medicinal cannabis for treating pain and 89% encourage using medicinal cannabis as terminal pain relief.

Medical Kiwi is in an exceptional position being among a couple of organizations in New Zealand using licences to be in a position to fully commercialise the opportunities which exist within this exciting and fast growth market.

It’s clear why so many Kiwi businesses are eager to break into the marketplace. There are lots of aspects that can contribute to New Zealand holding a strong international position inside the medicinal cannabis industry such as minding its natural strengths of climate and fertile soil, standing for innovation, renewable farming and agricultural practices along with world leading agronomic research and cropping experience.

A firm with a transparent plan and societal function

Launched in December 2018, Medical Kiwi is an early stage medicinal and health cannabis study and manufacture firm created to make the most of this emerging medicinal cannabis sector in New Zealand and the international opportunities that it symbolizes.

“We have a clear strategy for research, manufacturing, product, marketing, sales and distribution with an experienced board of Directors who bring to the table vast skills, knowledge and expertise and a proven track record of corporate governance,” states Miccio.

The business intends to take care of farming directly through the creation of fast evolving consumer products. “The seed to sale vertical integration approach will set Medical Kiwi apart from the bulk of other companies operating in New Zealand, which might focus solely on cultivation or research,” he states.

The strategy is for Medical Kiwi to come up with secure, high quality, reachable medicinal and nutraceutical products such as oils, balms, tinctures, sprays and lotions. Miccio finds potential in anything which may be consumed or placed on the skin to get a CBD range. “I was recently invited to a luxury goods conference in New York focusing on cannabis in luxury beauty goods and all the big brands were there.”

While there’s a strong business driveway supporting the business, the vision is that everybody who may benefit from medicinal and nutraceutical cannabis can get safe, effective high quality goods and manage them. “We have seen how medicinal cannabis can improve the lives of people and believe the products we will produce will effect real change in people’s lives and health outcomes,” additional Miccio.

Life-changing benefits in fibromyalgia sufferers

One individual to have observed firsthand the important — in some instances life-altering — developments to patients health and health is Medical Kiwi Director and Rheumatology professional, Dr David Porter.

“Porter’s knowledge and experience in this area is invaluable, not only to Medical Kiwi’s progress to becoming one of New Zealand’s leading cultivators and producers of high-grade medicinal and nutraceutical cannabis products, but also being at the forefront of helping the New Zealand community develop a greater understanding of the medical benefits of cannabis products,” states Miccio.

Porter has over 27 years’ experience in the medical profession. As a Consultant Rheumatologist, he supplies expert medical and nursing services to individuals with inflammatory and autoimmune disorders, in addition to fibromyalgia patients. Porter is enthusiastic about providing the maximum quality herbal and nutraceutical cannabis goods together with the considerable benefits that they bring to patients.

“About three years ago patients started telling me they had been looking locally to find a producer of CBD, which was at that time illegal in New Zealand,” states Porter. “They reported that not only was it the best, most effective treatment they had ever used, it didn’t cause any side effects. That feedback came back again and again and again.”

Porter was prescribing imported medicinal cannabis to over 100 fibromyalgia patients to its past 18 months as it became legal in New Zealand. Their response and treatment have been recorded using a standardised questionnaire.

“The lack of side effects is the most common feedback patients report and it is what stands medicinal cannabis in complete contrast to all other conventional drugs I have used to treat chronic pain,” states Porter. His job in the health agency treating and working with patients with chronic pain would be crucial to notifying Medical Kiwi’s development and research of medicinal cannabis and health solutions.

research and development: central to advancing the medicinal cannabis sector

During August, Medical Kiwi was awarded a permit to cultivate medicinal cannabis in the Ministry of Health — just the eighth business in New Zealand to obtain the license — that will let them set a cannabis breeding programme for development and research. “This was a significant milestone for Medical Kiwi and confirmation that in just eight months our experienced board of Directors has developed a clear strategy that is already on track,” remarked Miccio.

research and development are fundamental to improving the medicinal cannabis business and also to Medical Kiwi with innovative research encouraging the development of secure, higher quality medicinal cannabis solutions. Continuing development and research, with accelerated adoption of applicable global technological progress, will indicate the firm may be agile in its response to market demands and establish an elevated amount as leaders and leaders within the business.

Medical Kiwi Director, Dr Michael Packer is a natural merchandise biochemist with 28 years’ experience. He combined the Medical Kiwi group to help direct the rigorous evidence-based maturation of natural goods to help human health.

On the past 15 years he’s been concentrated on biotechnology in plants, particularly algae, an aquatic plant. “Natural products are often complex mixtures and there is huge potential to tailor the constituents of these extracts from plants to benefit human health,” states Packer.

“This can occur through processes such as extraction and formulation, but especially through the growth conditions of the source material. The product potential of plants is tremendously affected by their growth conditions, especially the lighting.” Packer has extensive experience exploring the consequences of lighting conditions on plant secondary metabolite production and the evolution of industrial processes out of this. As a Senior Research Scientist in the Cawthron Institute in Nelson, New Zealand, he oversees a indoor algal growth facility and has been engaged in establishing commercial algal farms to the biotechnology market.

He has extensive experience utilizing custom-built bespoke photobioreactors, allowing algal growth experiments under controlled conditions. A highly effective technique he uses in conjunction would be pulsed amplitude modulation (PAM) fluorescence to research several photosynthetic parameters suggesting that the ‘health’ of these plants affecting how they create the desirable natural products. In the past several decades a focus has become the formula and extraction of them, and also his work has concentrated on products with anti-inflammatory and antioxidant qualities, then their strict testing for favorable effect. These very same approaches can be immediately applied to the evolution of merchandise from cannabis.

“Dr Packer’s practical experience and successes give us a great platform to further research and develop solutions for health care issues that are controlled by the endocannabinoid system that cannabis has such a direct influence over,” states Miccio.

Medical Kiwi’s research program would be to produce collaborations with top academics and professionals in the area based on comprehending the bioactive components inside cannabis. “We will seek to research the effects of growth lighting conditions on cannabinoid outcomes, in a replicable way with the goal of establishing protectable proprietary products for different human conditions. Medical Kiwi will develop, or contribute to, certification of standardisation of the beneficial bioactive properties of cannabis extracts,” states Packer.

Construction international partnerships and collaborations

Strong overseas partnerships and collaborations are opening doors to global chances for Medical Kiwi. While Miccio was at the uk, he had the chance to meet up with two firms and obtain some insight into their operations. Among those firms was Vitality CBD.

As a consequence of this meeting and additional debate, Medical Kiwi and Vitality CBD have recently signed an exclusive supply arrangement which will empower Medical Kiwi to import and promote Vitality CBD goods the moment the medicinal cannabis strategy is operational from the first quarter of 2020.

This arrangement is an exciting step towards our approach to import and distribute our international spouse’s branded medicinal and nutraceutical products on a continuous basis to provide New Zealanders with access to secure, high quality, affordable products while our own locally cultivated Medical Kiwi goods are being manufactured,” states Miccio.

Medical Kiwi available for investment

The effective completion of stage one seed financing earlier this year increased NZ $1m (~$575,000), empowering Medical Kiwi to secure a eight-hectare greenfield site, complete design strategies for a state-of-the-art centre and apply for licences. The eight — ten million square metre complexes was especially engineered and designed to align environmental responsibility with commercial goals, such as technology to guarantee agricultural and business practices are renewable and harnessing solar energy to electricity the high-yield grow centre.

“If you want to power a facility using the sun’s energy, then Nelson in the South Island of New Zealand is the place to do it, boasting over 2,200 hours of sunshine each year earning the reputation as New Zealand’s sunshine capital,” states Miccio.

Nelson also has a lot of industrial things that led to the decision to foundation Medical Kiwi from the area. It is well-known as an agricultural hub for the South Island and is in the frontier of science.

Medical Kiwi’s centre will also include sophisticated security methods, world class growing facilities, growth special devices like climate control irrigation, lighting seat and extraction methods. The centre will be located for operational logistics and supply of merchandise.

“We expect our facility to reach full capacity in four years, with staged build costs over this period,” states Miccio. When in full production, estimated to be ancient 2024, the center is intended to produce 30 — 35 million tonnes of dried product per annum, valued now in between NZD $100 — $110 million.

Miccio has lately returned from a successful trip to London, Singapore and Hong Kong where he established stage two of Medical Kiwi’s investment deal; introducing to sophisticated investors and wholesale personal investor networks considering investing in the future of Medical Kiwi.

The stage 2, Series A Pre-IPO share provide seeks to increase an additional NZ $7.5 million of investment funds to help with establishing a Asian supply entity established in Singapore to permit international distribution arrangements for Medical Kiwi branded goods, in addition to establishing a New Zealand based supply to advance the plan, manufacturer and sales channel development.

Medical Kiwi’s Information Memorandum, on the site www.medicalkiwi.com and summarizes the organization’s planned business model and strategic aim.

Medical Kiwi in a glance

  • A medicinal cannabis study and nutraceutical company based in New Zealand;
  • Launched in December 2018 to benefit from this increasing demand and legislative changes producing original mover advantage;
  • Successfully raised NZ $1 million in seed financing, now trying to raise $7.5 million through a Series A Pre-IPO share provide;
  • Strategies for an eight to ten million square metre, state of the art center. When at full production it’s intended to produce 30 -35 million tonnes of dried merchandise, valued now at NZD $100 — $110 million;
  • Defined plan and roadmap, with clear milestones being achieved and partnerships created;
  • Strong governance together with applicable abilities in research and medical disciplines;
  • Positioned to create a proprietary intellectual property.
Share